Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13692380 | 1.00 | HTR2A (0.70) | HTR2AHSD17B10ADRA1AIDO1TAAR1 | |
| SCHEMBL9118398 | 0.86 | APLNR (0.56) | HTR2AADRA1AGABRA1GABRB2ADRA2A | |
| SCHEMBL4960829 | 0.85 | HTR2A (0.74) | HTR2AHSD17B10ADRA1AIDO1TAAR1 | |
| SCHEMBL6203717 | 0.84 | HTR2A (0.68) | HTR2AHSD17B10ADRA1AIDO1TAAR1 | |
| SCHEMBL8527544 | 0.83 | HTR2A (0.61) | HTR2AHSD17B10ADRA1AIDO1TAAR1 | |
| SCHEMBL9171220 | 0.82 | HTR2A (0.70) | HTR2AHSD17B10ADRA1AIDO1TAAR1 | |
| SCHEMBL1740902 | 0.82 | HTR2A (1.00) | HTR2AADRA1AIDO1TAAR1 | |
| SCHEMBL1740903 | 0.82 | HTR2A (1.00) | HTR2AADRA1AIDO1TAAR1 | |
| SCHEMBL3459466 | 0.82 | GABRA1 (0.54) | HTR2AGABRA1GABRB2GAA | |
| SCHEMBL4633299 | 0.82 | HTR2A (0.47) | HTR2AGABRA1GABRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102036990-B | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP. (US) | 2015-09-30 | — | — | CN | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8986846-B2 | Thermosetting oligomer or polymer, thermosetting resin composition including the oligomer or polymer, and printed circuit board using the composition | SAMSUNG ELECTRO-MECHANICS CO., LTD. (KR) | 2015-03-24 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| EP-2262807-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100155120-A1 | THERMOSETTING OLIGOMER OR POLYMER, THERMOSETTING RESIN COMPOSITION INCLUDING THE OLIGOMER OR POLYMER, AND PRINTED CIRCUIT BOARD USING THE COMPOSITION | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HTR2A 3742/4885HSD17B10 2321/4885ADRA1A 2190/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HTR2A 3742/4885HSD17B10 2321/4885ADRA1A 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.